TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Nursing home operators say GLP-1 medications are increasingly common among residents, including for conditions beyond diabetes and weight loss. Providers are adapting clinical monitoring, while payment remains unsettled: a Medicare bridge program runs through 2027, but a permanent coverage plan has no announced start date.
GLP-1 medications are increasingly arriving with nursing home residents, prompting operators to expand clinical monitoring and weigh the cost of treatment against potential health benefits. Leaders interviewed by Skilled Nursing News said use now extends beyond diabetes and weight loss, while Medicare’s more permanent coverage plan has been delayed.
Lisa Chubb, chief nursing officer for New Jersey-based Venza Care, said about 30% to 40% of newly admitted residents at the operator are taking GLP-1s, with a higher share at facilities that have more short-stay residents. She said staff are seeing prescriptions linked to cardiovascular prevention, metabolic conditions and organ health as well as the medications’ earlier, more familiar uses.
Venza has added weekly “nutrition at risk” meetings and electronic health record assessments to track residents’ medication reviews, education and weight changes. Registered dietitians are part of the interdisciplinary teams monitoring residents, Chubb said. The aim is to weigh treatment choices against possible complications, including muscle weakness and frailty.
Payment varies by coverage and setting. Jessie McGill, a senior curriculum development specialist at the American Association for Post-Acute Care Nursing, said a federal Medicare Part D bridge program covers certain drugs for eligible residents seeking weight-loss treatment, with a $50 monthly fee in addition to Part D coverage. The program applies to Wegovy, Zepbound and Foundeo, according to McGill. Residents may still struggle to pay the fee, and nursing homes may face the expense for some prescriptions during Medicare Part A stays.
Care Teams Face New Monitoring Demands
The expanding use of GLP-1s brings decisions about medication safety, nutrition and affordability into daily nursing home care. Residents may have frailty, multiple chronic conditions or functional limitations that differ from the populations commonly discussed in connection with these drugs. A weight-loss goal may not suit every resident, and the facility must consider how treatment fits an individual’s health and care plan.
Lauren Stenson, a curriculum development specialist with AAPACN, pointed to potential adverse effects including nausea, vomiting, constipation and dehydration. The report does not provide facility-wide outcome data, so it does not establish how often these effects occur among nursing home residents or what benefits the medications produce in this population. Operators’ descriptions instead show how facilities are preparing to monitor use while weighing clinical considerations against costs.
For nursing home operators, the payment question can affect admissions and operating budgets. Jody O’Mara, chief nursing officer for Journey Skilled Nursing, said high-cost medications may become a facility expense in its pharmacy joint venture. She argued that benefits can outweigh costs, but that is her assessment, not a reported cost-effectiveness finding. The coverage gap means residents and providers may face different bills based on prescription, benefit and stay type.
Products Worth Considering
VEVOR Walk-In Tunnel Greenhouse with Watering System, 15 x 7 x 7 ft
Orbit B-hyve XD 4-Port Smart Hose Watering Timer with Wi-Fi Hub
Solo Stove Pi Prime Portable Propane Pizza Oven
As an affiliate, we earn on qualifying purchases.
Medicare Coverage Is Still in Flux
Medicare Part D covers GLP-1s prescribed for diabetes, according to the source report. The bridge program offers limited coverage for certain drugs prescribed for weight loss when the resident has not already been prescribed a GLP-1 for diabetes. Eligibility also depends on criteria including BMI and other chronic conditions, McGill said.
A more permanent program, called BALANCE, was delayed without a new implementation date. The existing bridge program was extended through 2027. McGill said nursing homes may be responsible for medication costs for residents covered under Medicare Part A, particularly when a prescription does not qualify for the bridge program. She said one possible policy change would be expanding consolidated billing to cover high-cost drugs such as GLP-1s; the report does not say that change has been adopted.
“We see a lot of our new admissions coming in with GLP-1s. Initially it was used solely for weight loss and diabetes, but now we’re seeing it trend in other directions as well.”
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Resident Outcomes Remain Open
The report does not specify how many nursing home residents nationwide use GLP-1 medications, how prescribing varies by drug or diagnosis, or what clinical outcomes facilities have documented. Venza’s admission figures describe that operator, not the sector as a whole. The balance of benefits and risks for older, frail residents is also not quantified in the material provided.
It is also unclear when or whether the BALANCE program will take effect, what its final coverage terms would be, or whether Congress will change consolidated billing. The bridge program’s extension through 2027 offers a defined period of coverage, but does not resolve what payment arrangements will follow.
Facilities Track Care and Coverage Changes
In the near term, nursing homes will continue to review residents’ prescriptions, monitor nutrition and weight, and account for medication expenses under the coverage rules currently in force. Venza’s meetings and assessments offer one example of the added processes operators say they are using; the source does not establish that all facilities follow the same approach.
Providers and residents will also need to watch for updates on the bridge program and any revised date or terms for BALANCE. McGill identified congressional expansion of consolidated billing as a potential route to changing how facilities pay for some high-cost drugs, but no such policy change was confirmed in the report.
Key Questions
How common are GLP-1 medications among nursing home residents?
At Venza Care, Lisa Chubb said about 30% to 40% of new admissions are taking GLP-1s. The figure is specific to Venza and is higher at its facilities with more short-stay residents; it is not a national estimate.
Which GLP-1 drugs are covered by the bridge program?
AAPACN’s Jessie McGill said the program covers Wegovy, Zepbound and Foundeo for eligible residents under its rules. Coverage and eligibility depend on the prescription and other criteria.
What does the bridge program cost residents?
McGill said the program adds a $50 monthly fee alongside Medicare Part D coverage. That fee may remain a barrier for residents who cannot afford it.
Why do nursing homes monitor GLP-1 use closely?
Care teams must account for residents’ nutrition, frailty and other health conditions. AAPACN’s Lauren Stenson cited possible side effects such as nausea, vomiting, constipation and dehydration; the report does not give rates for these effects among nursing home residents.
When will permanent Medicare coverage begin?
The report says the proposed BALANCE program was delayed without a new implementation date. The existing bridge program was extended through 2027.
Source: skillednursingnews.com
